NCT02741817 (WILLOW-ACS) is a Phase 4 clinical trial of Aspirin in Acute Coronary Syndrome, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.

Who is sponsoring NCT02741817?

NCT02741817 is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.

What drugs are being tested in NCT02741817?

Interventions in NCT02741817: Aspirin.

What condition does NCT02741817 study?

NCT02741817 studies Acute Coronary Syndrome.

Is NCT02741817 still recruiting?

NCT02741817 is currently completed. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT02741817: WILLOW-ACS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)

Completed Phase 4 Last updated 17 March 2021

What this trial tests

Phase 4 trial testing Aspirin in Acute Coronary Syndrome in 20 participants. Completed in 7 April 2017.

Timeline

26 June 2016

Primary endpoint
7 April 2017

7 April 2017

Quick facts

Lead sponsor	Sheffield Teaching Hospitals NHS Foundation Trust
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	prevention
Enrollment	20
Start date	26 June 2016
Primary completion	7 April 2017
Estimated completion	7 April 2017
Sites	1 location across United Kingdom

Drugs / interventions tested

Aspirin — full drug profile →

Conditions studied

Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Who can join

18 and older, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is going to compare two different doses of aspirin for the treatment of heart disease in combination with the anticlotting medication ticagrelor. One of these doses of aspirin, 75 milligrams (mg) once a day, is the current standard treatment dose of aspirin used to treat heart attacks and angina. The other, 20 mg twice a day, is lower than the standard but there is growing scientific evidence that, when given with ticagrelor, this might offer advantages over the usual dose.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome.
Parker WAE, Orme RC, Hanson J, Stokes HM, et al · · 2019 · cited 23× · PMID 30759035 · DOI 10.1080/09537104.2019.1572880

Verify or expand the search:

Other trials of Aspirin

Trials testing the same drug.

NCT07525635 — Aspirin Dosing in Pregnancy · EARLY_PHASE1 · not yet recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
NCT07373756 — Randomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk · Phase 4 · not yet recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06638151 — Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) · Phase 2 · recruiting

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting

Other Sheffield Teaching Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07407712 — Better Outcomes Through Optimal Sleep in Surgical Training · NA · recruiting
NCT07172555 — Virtual Dietetic Interventions in Patients With Coeliac · NA · recruiting
NCT06310993 — Exercise to Boost Immunity in Advanced Cancer · NA · not yet recruiting
NCT06905405 — The Use of Advanced Imaging in HFpEF · recruiting
NCT06633627 — Neurological Responses in Patients with Dentine Hypersensitivity · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02741817 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheffield Teaching Hospitals NHS Foundation Trust
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02741817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing